US Edition
What to Know About the 2025 Waco Walk to End Alzheimer's
NEW YORK, UNITED STATES, JUL 22 – Eisai will share four-year data on lecanemab's long-term safety and efficacy, including a new subcutaneous dosing option to improve treatment convenience for Alzheimer's patients.
- On Wednesday, July 30, in Toronto, Eisai presents initial four-year findings from the Phase 3 Clarity AD open-label extension trial, during the “Developing Topics Session: Innovative Therapeutic Approaches”.
- Ahead of the session, Eisai outlined scope of data including real-world evidence, subcutaneous formulation for maintenance dosing.
- To date, lecanemab holds regulatory approval in 16 countries including the U.S., Japan, and the European Union, broadening its global reach, Eisai said.
- In a session, Lynn D. Kramer emphasized `data presented at AAIC 2025 will highlight long-term findings`, noting treatment flexibility with subcutaneous formulation for patients.
- Future studies include the DIAN-TU Tau NexGen trial, which has included lecanemab since January 2022, to explore disease modification in early Alzheimer's disease.
80 Articles
80 Articles
What to know about the 2025 Waco Walk to End Alzheimer's
WACO, Texas (FOX 44) - The 2025 Waco Walk to End Alzheimer's is taking place on Saturday, October 11th, and FOX 44 is a proud sponsor! Harbor Hospice community education coordinator Casey Tusa paid a visit to our studio to tell us more about the event. You can watch our interview above.
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau …
Globe Newswire
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations...
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 - Biogen (NASDAQ:BIIB)
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations …
Several studies have demonstrated the effectiveness of certain blood tests in detecting the internal signs of the disease. A novelty that could "change the way we make the diagnosis", according to.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
